A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Trial Profile

A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Suspended
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs BI 425809 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 08 Feb 2017 Planned End Date changed from 1 Apr 2019 to 1 Sep 2020.
    • 08 Feb 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Aug 2020.
    • 03 Oct 2016 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top